PCSK9 inhibitor
Also written as: PCSK9 — Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
Injectable cholesterol-lowering medication class reserved for high-risk patients inadequately controlled with statins.
Full Definition
A class of monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9), thereby increasing LDL receptor recycling and dramatically reducing LDL cholesterol levels. These injectable medications (alirocumab, evolocumab) are typically reserved for patients with familial hypercholesterolemia or established cardiovascular disease who cannot achieve LDL goals with maximally tolerated statin therapy. The high cost and injection requirement limit their use to specific high-risk populations with inadequate response to conventional therapy.
Usage
Usage note: Always capitalize PCSK9; reserved for specific high-risk populations.
In Context
- "PCSK9 inhibitor therapy achieved target LDL-C levels in this statin-intolerant patient." — Treatment response note
- "Insurance approval for PCSK9 inhibitors requires documentation of inadequate statin response." — Prior authorization form